Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Publications and patents in corporate venture–backed biotech

Nature Biotechnology volume 31, pages 495–497 (2013)Cite this article

Subjects

To the Editor:

Biotech startups increasingly turn to corporate venture capital (VC) arms for funding, rather than to traditional venture capitalists. The innovation implications for these startups remain unexplored. Here, we present evidence that the shift in funding patterns is associated with a greater output of scientific publications as well as patenting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: At-a-glance distribution of biotech startups across innovation categories (based on whether startup leads or lags the median output of its age cohort) by investor type (corporate VC–backed startups versus solely traditional VC–backed startups), at time of investment and four years later.

References

  1. von Krogh, G., Battistini, B., Pachidou, F. & Baschera, P. Nat. Biotechnol. 30, 911–915 (2012).

    Article  CAS  Google Scholar 

  2. Huggett, B. Nat. Biotechnol. 30, 395–400 (2012).

    Article  CAS  Google Scholar 

  3. Griliches, Z. J. Econ. Lit. 28, 1661–1707 (1990).

    Google Scholar 

  4. Agrawal, A. & Henderson, R. Manage. Sci. 48, 44–60 (2002).

    Article  Google Scholar 

  5. PricewaterhouseCoopers. Corporate venture capital activity on three-year upward trend. <http://www.pwc.com/us/en/press-releases/2012/q4-2011-corp-vc-press-release.jhtml> (2012).

  6. Flinn, R. Corporate venture funds boost biotech startups. <http://www.sfgate.com/business/article/Corporate-venture-funds-boost-biotech-startups-2289454.php> (SFGate, 15 November 2011).

  7. Singh, V. The Burrill Report 2, 10 (2012).

    Google Scholar 

Download references

Acknowledgements

Funding from the Mack Center (the Wharton School) is greatly appreciated.

Author information

Authors and Affiliations

  1. Georgia State University, Atlanta, Georgia, USA

    Elisa Alvarez-Garrido

  2. London Business School, London, UK

    Gary Dushnitsky

Authors
  1. Elisa Alvarez-Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary Dushnitsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Elisa Alvarez-Garrido or Gary Dushnitsky.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1 and 2 (PDF 30 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alvarez-Garrido, E., Dushnitsky, G. Publications and patents in corporate venture–backed biotech. Nat Biotechnol 31, 495–497 (2013). https://doi.org/10.1038/nbt.2569

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2569

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing